Information Provided By: 
Fly News Breaks for July 18, 2016
AZN, VRX
Jul 18, 2016 | 07:37 EDT
Canaccord noted the FDA released briefing documents for its upcoming advisory committee review of brodalumab, Valeant's drug for the treatment of moderate to severe plaque psoriasis in adults. The agency raised concerns about the incidence of suicide and major cardiovascular events. Canaccord feels the safety concerns could limit the drug's potential. Canaccord maintains its Hold rating and $28 price target on Valeant shares.
News For VRX;AZN From the Last 2 Days
AZN
Apr 25, 2024 | 05:52 EDT
Consensus $4.56. Backs FY24 revenue view up low double-digit to low teens percentage, consensus $50.95B. Sees FY24 core tax rate 18%-22%.
AZN
Apr 25, 2024 | 05:49 EDT
AZN
Apr 23, 2024 | 11:16 EDT
Bearish flow noted in AstraZeneca with 3,362 puts trading, or 1.7x expected. Most active are 4/26 weekly 70 puts and May-24 70 calls, with total volume in those strikes near 3,600 contracts. The Put/Call Ratio is 1.72, while ATM IV is up nearly 2 points on the day. Earnings are expected on April 25th.
